Aytu BioPharma Reports Third Quarter 2022 Financial Results and Outlines Key Strategic Priorities
16.05.2022 - Quarterly Net Revenue Increased 79% Year-Over-Year to $24.2 Million, the Highest Revenue in Company HistoryStrategic Priorities Focused on Driving Revenue Growth, Increasing Financial Efficiencies and Performance and Preparing Pipeline for Long-term ...
Source: wallstreet-online.de